Poster Abstract Tracks/Topics (Review Groups)

AAPS **PharmSci 360** will combine all the energy of a large scientific conference with the intimacy of a small niche gathering.

There are five robust tracks covering all aspects of the pharmaceutical sciences, including both chemical and biomolecules.

IMPORTANT Note: in the submission site, the structure below; Track, Subtrack, Primary Topic, Subtopic, and Secondary Topic, are referred to as Review Groups. You will be prompted to select the Review Group that best fits your abstract.

Review Group (Track/Topic) Selection Process

- 1. Select the Track that best fits your research. (see below)
- * Preclinical Development
- * Bioanalytics
- * Clinical Pharmacology
- * Manufacturing and Bioprocessing
- * Formulation and Quality
- 2. Select the Subtrack (Biomolecules or Chemical Entity).
- 3. Select the Primary Topic that best fits your research.
- 4. From your Primary Topic, select the best Subtopic for your research. If no listed term fits your research, select 'Other'. (*Note: There may not be a subtopic available for your Primary Topic.*)
- 5. If your Subtopic shows Secondary Topic choices, make the best selection. If no listed term fits your research, select 'Other'. (*Note: There may not be a Secondary Topic available for your Subtopic.*)

TRACK	SUBTRACK	PRIMARY TOPIC	SUBTOPIC	SECONDARY TOPIC
Bioanalytics	Biomolecules	ADCs and Peptide Quantification	Electrospray Ionization Hybrid LBA/LCMS Ligand Binding Assay (LBA) Other	
		Bioanalytical Innovations and Applications		
			Biomarker/Pharmacodynamic Measurement	
			Methods to Assess Disease Heterogeneity	

Biomarker Quantification	Target Engagement/Receptor	
	Occupancy	
	Technologies other than LBA and Mass	
	Spec (e.g., Flow, PCR)	
	Other	
	Endogenous Homologs Quantification	
	Other Methods/Techniques	
		Intact
		Free
Drug Quantification	Pharmacokinetic Measurements	Surrogate
		Total
		Other
	Post-Marketing Commitment	
	Therapeutic Drug Monitoring	
	ADA Test Methods	
	Cell-Based Methodologies	
Immunogenicity	Immunogenicity Risk Assessments	
	Neutralizing Antibody Methods	
	Other	
	Evaluation of Biotransormation In Vivo	
	Impact of Biotransformation on	
In Vivo and Ex Vivo Biotransformation	Immunogenicity	
	Impact of Biotransformation on PK	
	Molecule Variants Quantification Ex Vivo	
	Collaboration with Other Partners (Co-	
	development)	
Life Cycle Management of Bioanalytical	General Life Cycle Management	
Methods	Methods Transfer and CRO	
	Management	
	Other	
	ADCs	
	Alternative Scaffold	
	CAR-T	
	Cell-Based Therapy	
	Encapsulated Drugs (Lipid,	
Novel Modalities	Nanoparticle, and Viral Vectors)	
	Multi-specific Antibodies	
	Nanoparticle Based Modalities	
	Oligos, RNAs and Locked Nucleic Acids	
	Other	
Other		

			Life Cycle Management	
			Quality Control and Characterization	
		Trougerile aria recordings Grandarus	Stability	
			Other	
			Biomarkers	
			Drug (and Metabolites)	
			GCP/GLP Compliance for Bioanalytical	
			Labs	
			General Topics	
		Regulations (BMV/GLP/GCP/CLIA)	ICH	
			Immunogenicity	
			Samples and Reagent Stability	
			Bioanalyticsl Risk Assessment and	
			Strategy (Tiered Strategies)	
			Other	
			Laboratory Information Management	
			System (LIMS)	
		Samples and Laboratory Management	Microsampling and Dried Blood Spots	
		Samples and Laboratory Management	Post-Collection Sample Condition and	
			Record Management	
			Other	
			Methods/Techniques	
		Vaccines	Protective Titer Assessment	
			Other	
	Chemical Entities		Electrospray Ionization	
		ADCs and Pontide Quantification	Hybrid LBA/LCMS	
		ADCs and Peptide Quantification	Ligand Binding Assay (LBA)	
			Other	
			Ex Vivo	
		Analyte Stability	In Vitro	
			Other	
		Applications		
			Biomarker/Pharmacodynamic	
			Measurement	
			Methods to Assess Disease	
		Biomarker Quantification	Heterogeneity	
			Target Engagement/Receptor	
			Occupancy	
			Technologies Other than Mass Spec	
			(e.g., PCR)	
			Other	

	Endogenous Homologs Quantification	
	_	
Drug Quantification	Other Methods/Techniques	
3	Pharmacokinetic Measurements	
	Therapeutic Drug Monitoring	
Immunogenicity	ADA Test Methods	
minunogementy	Other	
	CYP450 Assessment	
	Evaluation of Biotransformation In Vitro	
	or In Vivo	
1.70 15.70 50 6 6	Impact of Biotransformation on	
In Vivo and Ex Vivo Biotransformation	Immunogenicity	
	Impact of Biotransformation on PK	
	Metabolite Quantification	
	Other	
	Collaboration with Other Partners	
	(Co-development)	
Life Cools Management of Discool ties	General Life Cycle Management	
Life Cycle Management of Bioanalytical Methods		
ivietnous	Methods Transfer and CRO	
	Management	
	Other	
	Alternative Scaffold	
	Encapsulated Drugs (Lipid, Nanoparticle	
	and Viral Vectors)	
Novel Modalities	Multispecific Antibodies	
	Nanoparticle Based Modalities	
	Oligos and Locked Nucleic Acids	
	Other	
Other		
	Life Cycle Management	
Decreased Defender Of an dead	Quality Control and Characterization	
Reagents and Reference Standards	Stability	
	Other	
	Biomarkers	
	Drug (and Metabolites)	
	GCP/GLP Compliance for Bioanalytical	
	Labs	
	General Topics	
Regulations (BMV/GLP/GCP/CLIA)	ICH	
(DIN V/OLI /OCI /OLI/1)	Immunogenicity	
	Samples and Reagent Stability	
	Bioanalyticsl Risk Assessment and	
	Strategy (Tiered Strategies) Other	
	Oute	

		Samples and Laboratory Management	Informed Consent Laboratory Information Management Systems (LIMS) Microsampling and Dried Blood Spots Post-collection Sample Condition and Record Management Other	
--	--	-----------------------------------	--	--

TRACK	SUBTRACK	PRIMARY TOPIC	SUBTOPIC	SECONDARY TOPIC
Clinical Pharmacology	Biomolecules		Bayesian Methods	
			Regulatory Recommendations	
		Biostatistical Methodologies	Statistical Analysis Models	
		Diostatistical Methodologies	Statistical Reporting	
			Tools/Software	
			Other	
			Designs and Methodology	
			Dosing Strategies	
			Ethics in Clinical Trials	
		Clinical Trials	Modeling and Simulation	
		Cililical Thais	Monitoring	
			Patient Stratification	
			Regulatory Guidance	
			Other	
			ADA	
		Immunogenicity	Clinical Relevance	
		ininunogenicity	Neutralizing Antibody	
			Other	
			ADME	
			Biomarkers/Pharmacodynamic	
			Measures	
		In Vitro Studies	Blood to Plasma Partitioning	
		III VIIIO Studies	Drug Transport and Drug Interactions	
			Genetic Variation/PGx Testing	
			Protein Binding	
			Other	
			ADCs	
			Alternative Scaffold	
			CAR-T	
			Cell-Based Therapy	
			Encapsulated Drugs (Lipid, Nanoparticle	
		Modalities	and Viral Vectors)	
		iviodalities	Multispecific Antibodies	
			Nanoparticle-Based	
			Oligos, RNAs and Locked Nucleic Acids	
			Vaccines	
			Other	

		Absorption Model	
		Allometric Scaling	
		Comparator Modeling	
		Decision Making	
		Dose Project/Selection/Justification	
		Imaging Based Approach	
		In Vivo-In Vitro Correlation (IVIVC)	
		Modeling	
		Maternal/Fetal PK Model	
	Modeling and Simulation	Pediatric Model	
	INIOGERING AND SIMULATION	Pharmacometrics	
		Physiologically Based Pharmacokinetics	
		(PBPK) Model	
		PK/PD Modeling	
		Population PK Modeling	
		Quantitative Systems Pharmacology	
		(QSP)	
		Tools/Software	
		Other	
	Other		
		CDISC	
		Clinical Study Reports (CSRs)	
		Clinical Trial Protocols	
		CTD/eCTD Models 1 to 5	
		Data Management	
	Regulatory Guidance/Submissions	FDA/EMA/PMDA Meetings	
		Labeling	
		NDA/BLA/ANDA Submissions	
		Safety	
		Other	
		Bioequivalence/Biosimilars	
		Diseased Population	
		Drug-Drug Interaction (DDI)	
		First-Time-in-Human (FTIH)	
		Food Effect	
		Geriatric	
	Time of Human Chief	Multiple Ascending Dose (MAD)	
	Type of Human Studies	Pediatric	
		Radio-Labeled Mass Balance and	
		ADME	
		Relative and Absolute BA	
		Single Ascending Dose (SAD)	
		Thorough QT/QTc (TQT)	
		Other	

Chemical Entities		Bayesian Methods	
		Regulatory Recommendations	
		Statistical Analysis Models	
	Biostatistical Methodologies	Statistical Reporting	
		Tools/Software	
		Other	
		Designs and Methodology	
		Dosing Strategies	
		Ethics in Clinical Trials	
	Clinical Trials	Modeling and Simulation	
	Clinical Thais	Monitoring	
		Patient Stratification	
		Regulatory Guidance	
		Other	
		ADME	
		Biomarkers/Pharmacodynamic	
		Measures	
	In Vitro Studies	Blood to Plasma Partitioning	
	III VIIIO Gladica	Drug Transport and Drug Interactions	
		Genetic Variation/PGx Testing	
		Protein Binding	
		Other	
		Absorption Model	
		Allometric Scaling	
		Comparator Modeling	
		Decision Making	
		Dose Project/Selection/Justification	
		Imaging Based Approach	
		In Vivo-In Vitro Correlation (IVIVC)	
		Modeling Maternal/Fetal PK Model	
		Pediatric Model	
	Modeling and Simulation		
		Pharmacometrics	
		Physiologically Based Pharmacokinetics (PBPK) Model	
		PK/PD Modeling	
		Population PK Modeling	
		Quantitative Systems Pharmacology	
		(QSP)	
		Tools/Software	
		Other	

Bioequivalence/Biosimilars Diseased Population Drug-Drug Interaction (DDI) First-Time-in-Human (FTIH) Food Effect Geriatric Multiple Ascending Dose (MAD) Pediatric Radio-Labeled Mass Balance and ADME Relative and Absolute BA Single Ascending Dose (SAD)	Regulatory Guidance/Submissions	CDISC Clinical Study Reports (CSRs) Clinical Trial Protocols CTD/eCTD Models 1 to 5 Data Management FDA/EMA/PMDA Meetings Labeling NDA/BLA/ANDA Submissions Safety Other	
Thorough QT/QTc (TQT) Other	Type of Human Studies	Diseased Population Drug-Drug Interaction (DDI) First-Time-in-Human (FTIH) Food Effect Geriatric Multiple Ascending Dose (MAD) Pediatric Radio-Labeled Mass Balance and ADME Relative and Absolute BA Single Ascending Dose (SAD) Thorough QT/QTc (TQT)	

TRACK	SUBTRACK	PRIMARY TOPIC	SUBTOPIC	SECONDARY TOPIC
Formulation and Quality	Biomolecules		In-Use Compatibility	
•			Nasal/Pulmonary	
			Ocular	
		Administration	Otic	
			Strategies	
			Trans-dermal	
			Other	
			(Sub)Visible Particles	
			Excipients	
			Impurities	
				Cell Therapy
				Free Oligonucleotide
				Gene Therapy
		Analytical	Modality Specific Methods	Protein
				Vaccine/Tolerance Induction
				Other
			New Technology	
			Potency/Bioassay	
			Other	
			Extended Release (Non-implant)	
			Implants	
				Ocular
		Drug Delivery	Other Deutes of Administration	Otic
			Other Routes of Administration	Trans-dermal and Topical
				Other
			Other	
			Design Control	
			Hardware	
		Drug Delivery, Devices, and Drug	Human Factor Engineering	
		Device	New Delivery Technologies	
			Patient-Centric Development	
			Software	
			Cell Therapy	
			Free Oligonucleotide	
			Gene Therapy	
				Developability Assessment
				Excipients
		Formulation		General Liquid Formulation Topics
		i ominianon	Protein	Syringes
				High-Throughput Screening
				Lyo
				Other

		Vaccine/Tolerance Induction	
		Other	
	Other		
		Compatibility	
		Container Closure Integrity	-
	Primary Packaging	Extractables/Leachables	_
		New Materials	
		(Sub)visible Particles	
		Accelerated Approval Pathways	
		Bioequivalence	
		Biosimilars	
		Innovative Technologies	
	Regulatory Considerations	Inspections and GMP's	
		Large Market Developments	
		New Regulations and Guidances	
		Risk Assessment Implementation	
		Smaller Market Developments	
		Stability Requirements	
Chemical Entition	es		Biorelevant Dissolution
			Cascade Impaction
		Drug Release Measurement	Dissolution
			Drug Release from Other Dosage Forms
			Other
		Excipients	
			Forced Degradation
	Analytical	languaities and Desardation	Impurity Quantitation
		Impurities and Degradation	In Silico Predicsion of Stability
			Other
		Method Development Strategies	
		New Analytical Technologies	
		Process Analytical Technology and	
		Continuous Release Testing	
		Other	
		BCS, DCS	
		Bioequivalence (also Regulatory)	
	Diambana autia	Comparability Assessments	
	Biopharmaceutics	IVIVC	
		Predictive Modeling	
		Other	

		Extended Release (Non-implant)	
		Implants	
			Ocular
	Drug Delivery		Otic
	Drug Delivery	Other Routes of Administration	Trans-dermal and Topical
			Other
		Other	
		Design Control	
		Hardware	
	Drug Delivery, Devices, and Drug	Human Factor Engineering	
	Device	New Delivery Technologies	
	Device	Patient-Centric Development	
		Software	
		Amorphous and Co-crystal Systems	
		Bioavailability Enhancement	
		Drug Substance Properties	
		Excipients	
		Fixed Dose Combinations Inhalation and Nasal	
	Formulation	innalation and Nasai	
		Oral	Immediate Release Modified Release
		Parenterals	
		Preformulation	
		Special Populations	
		Other	
	Other		
		Compatibility	
		Container Closure Integrity	
	Primary Packaging	Extractables/Leachables	
		New Materials	
		(Sub)visible Particles	
		Accelerated Approval Pathways	
		Bioequivalence	
		Biosimilars	
		Innovative Technologies	
	Regulatory Considerations	Inspections and GMP's	
	Regulatory Considerations	Inspections and Gives	
	Regulatory Considerations		
	Regulatory Considerations	Large Market Developments	
	Regulatory Considerations	Large Market Developments New Regulations and Guidances	
	Regulatory Considerations	Large Market Developments New Regulations and Guidances Risk Assessment Implementation	
	Regulatory Considerations	Large Market Developments New Regulations and Guidances Risk Assessment Implementation Smaller Market Developments	
	Regulatory Considerations	Large Market Developments New Regulations and Guidances Risk Assessment Implementation	

TRACK	SUBTRACK	PRIMARY TOPIC	SUBTOPIC	SECONDARY TOPIC
Manufacturing and	Biomolecules		Computer Validation	
Bioprocessing		Automation	Other	
			Biosimilarity Assessment	
		Biosimilar Manufacturing	Patent Protection	
			Other	
				Filling
			Aseptic Technologies and Sterilization	Filtration
			Aseptic reciliologies and Sternization	Mixing
				Other
			Cell Therapies	
			Freezing and Thawing	
			Lyophilization and Drying Technologies	
			Manufacturing and Assembly of	
			Drug/Device Combinations	
			Manufacturing of Drug Delivery Systems	
				Container Closure Integrity
		Drug Product Manufacturing and		Syringes
		Development	Primary Packaging	Vials
				Other
			Process Optimization	
			Protein Aggregation during Processing	
			and Immunogenicity	
			Secondary Packaging	
			Storage Considerations	
			Vaccines	
			Viral and Non-viral Vectors and Gene	
			Therapy	
			Visible and Subvisible Particles	
			Visual Inspection	
			Other	
			API Packaging and Storage	
			Cell Line Development	
			Cell Therapies	
			Clonality Assessments	
			Expression Systems	
			Genetic and Cell Line Engineering	
			Mammalian Cell Fermentation	
		Drug Substance Manufacturing and	Media Development Microbial/Yeast Fermentation	
		Development		
			Process Optimization	

	Protein Aggregation during Processing and Immunogenicity	
	Purification and Virus Removal	
	Vaccines	
	Viral and Non-viral Vectors and Gene	
	Therapy	
	Other	
	Change Control	
	CMO Management	
	Drug Master Files	
	Drug Substance and Drug Product	
	Shipment	
	Electronic Records	
	Handling Control Substances (DEA)	
	Inspections and GMP	
General Aspects and Strategies	Lean Manufacturing	
	Life Cycle Management	
	Manufacturing Economics	
	Materials Management and	
	Warehousing	
	Regulatory Strategy	
	Supply Chain	
	Other	
	Containment and Isolators	
Health, Safety, and Environment	High-Potent Drug Manufacturing	
Health, Salety, and Environment	OEL and PDE	
	Other	
	For Use in Drug Product Manufacture	
Innovative/Novel Processing		
Technologies and Concepts	For Use in Drug Substance Manufacture	
	Other	
	For Use in Drug Product Manufacture	
Integrated and Continuous Processing		
and Manufacturing	For Use in Drug Substance Manufacture	
	Other	
Manufacture of Clinical Supplies	Blinding of Comparator Drugs	
	Phase Appropriate GMP	
Other	Other	
Other		

			Clean Media	
			Facility Design	
			Media	
			Media Fills	
		D E		
		Plant Engineering and Maintenance	Modeling and Scheduling Multiproduct	
			Batch Plants	
			Modular Manufacturing	
			Plant Incident Investigations	
			Other	
			Cleaning Validation	
			Control of Impurity Formation	
			In-Process Controls	
			Process Analytical Technology and	
			Parametric/Real-Time Release	
			Process Modeling and Simulations	
			Process Validation	
		Process Design and Controls		
		Process Design and Controls	QbD and Assessment of Process	
			Parameters	
			Scale-Up/Process Transfers	
			Statistical Process Controls and Six	
			Sigma	
			Use of Prior Knowledge and Risk-Based	
			Approaches	
			Other	
			For Use in Drug Product Manufacture	
		Single-Use and Disposable Systems	For Use in Drug Substance Manufacture	
		, ,	Leachables and Extractables	
			Other	
	Chemical Entities		Computer Validation	
	Chemical Littles	Automation	Other	
				Filling
			Aseptic Technologies and Sterilization	Filtration
				Mixing
				Other
			Freezing and Thawing	
				Oral and Topical Liquids
			Liquius Mariuracture	Other
			Lyophilization and Drying Technologies	
			Manufacturing and Assembly of	
			Drug/Device Combinations	
			Manufacturing of Aerosols and DPI	
			U TTTT	
			Manufacturing of Drug Delivery Systems	
			and a starting of 2 and 2 on the starting of t	

			Distant
	Drug Product Manufacturing and		Blisters
	Development	Primary Packaging	Bottles
	Development		Container Closure Integrity
		Process Optimization	
		Secondary Packaging	
			Cremes
		Semi-solids Manufacture	Nanoemulsions, Nanocapsules,
			Liposomes, Solid Lipid Nanoparticles
			Other
			Capsules
		Oall de Marenta et ma	Powders
		Solids Manufacture	Tablets and Granules
			Other
		Storage Considerations	
		Visual Inspection Other	
		API Kilo Lab	
		API Packaging and Storage	
		Control of Impurity Formation	
		Crystal Structure/Polymorph Screening	
		Crystallization Development	
	Drug Substance Manufacturing and	Filtration	
	Development	Genotoxic Impurities	
		Milling and Micronization Technologies	
		Particle Size Control	
		Process Chromatography	
		Process Optimization	
		Purification	
		Other	
		Change Control	
		CMO Management	
		Drug Master Files	
		Drug Substance and Drug Product	
		Shipment	
		Electronic Records	
		Handling Control Substances (DEA)	
	General Aspects and Strategies	Inspections and GMP	
		Lean Manufacturing	
		Life Cycle Management	
		Manufacturing Economics	
		Materials Management and	
		Warehousing	
		•	

_		_
	Regulatory Strategy	
	Supply Chain	
	Other	
	Patent Protection	
Canaria Manufacturina	Pharmaceutical Equivalence	
Generic Manufacturing	Assessment	
	Other	
	Containment and Isolators	
	Explosion Protection	
	Green Chemistry	
Health, Safety, and Environment	High-Potent Drug Manufacturing	
	OEL and PDE	
	Solvent Recovery	
	Other	
	For Use in Drug Product Manufacture	
Innovative/Novel Processing Technologies and Concepts	For Use in Drug Substance Manufacture Other	
	For Use in Drug Product Manufacture	
Integrated and Continuous Processing and Manufacturing	For Use in Drug Substance Manufacture Other	
	Blinding of Comparator Drugs	
Manufacture of Clinical Supplies	Phase Appropriate GMP	
	Other	
Other		
	Clean Media	
	Facility Design	
	Media	
	Media Fills	
Plant Engineering and Maintenance	Modeling and Scheduling Multiproduct Batch Plants	
	Modular Manufacturing	
	Plant Incident Investigations	
	Other	
	Cleaning Validation	
	Control of Impurity Formation	
	In-Process Controls	
	Process Analytical Technology and	
	Parametric/Real-Time Release	
	. a.alotilo/1toal 1iillo 1toloado	

	Parameters Scale-Up/Process Transfers Statistical Process Controls and Six Sigma Use of Prior Knowledge and Risk-Based Approaches Other For Use in Drug Product Manufacture	
· · ·	For Use in Drug Substance Manufacture Leachables and Extractables Other	

TRACK	SUBTRACK	PRIMARY TOPIC	SUBTOPIC	SECONDARY TOPIC
Preclinical Development	Biomolecules	ADME	In Vitro	Metabolizing Enzymes
				Protein Binding
				Transporter
				Other
			In Vivo	
			Pharmacokinetics	
			Other	
				In Silico
				In Vitro
			Biology	In Vivo
			ыоюду	Receptor/Target Interactions
				Target Identification
				Other
				In Silico
			Biology/Efficacy	In Vitro
				In Vivo
			Chemistry	Structure Activity Relationships
				Other
			Conjugation	
			Novel Drug Modality	
		Discovery	Payload-Linker	
			Identification/Optimization	
			Protein/Gene Engineering and	
			Expression	
			Receptor/Target Interactions	
			Structure Activity Relationships	
			Target Identification and Selection	=
			Vaccines	Antigen Evaluation
				Disease and Pathogen Evaluation
				Immunogenicity
				Innate/Adaptive Immunity
			Novel Delivery Strategies	
				Parasite Biology
				Preclinical Formulation and Adjuvants Other
			Other	Outo
		OMICS		
			Genomics Metabolomics	
			Proteomics	
		Other	1 10100111100	
		Culoi		

		Cellular and Molecular Toxicity	
		De-risking Strategies	
		Immuno-toxicity	=
	Safety	IND Enabling Studies	-
		Mechanistic Toxicity	1
		Screening Toxicity Studies	†
		Other	-
		Drug-Drug Interactions	
			Allometric
		Human Dose Projections	(PBPK)
	Translation	Truman Bose Frojections	Other
	Translation	Model Based Drug Development	
		PK/PD	1
		Other	
Chemical Entities			Metabolizing Enzymes
C.I.C.IIIOGI EIIIIIIOO			Protein Binding
		In Vitro	Transporter
	ADME		Other
		In Vivo	
		Pharmacokinetics	
		Other	
			In Silico
			In Vitro
		D: 1	In Vivo
		Biology	Other
			Receptor/Target Interactions
	Discovery		Target Identification
		Chemistry	Structure Activity Relationships
			Other
		In Silico	
		In Vitro	
		In Vivo	
		Novel Drug Modality	
		Target Interactions	
		Other	
		Genomics	
	OMICS	Metabolomics	
		Proteomics	
	Other		

		Cellular and Molecular Toxicology	
	Safety	De-risking Strategies	
		Immuno-toxicity	
		IND Enabling Studies	
		Mechanistic Toxicity	
		Screening Toxicity Studies	
		Other	
	Translation	Drug-Drug Interactions	
			Allometric
		Human Dose Projections	Physiologically Based Pharmacokinetics (PBPK) Other
		Model Based Drug Development	
		PK/PD	
		Other	